Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE

8. Gilead Sciences, Inc. (NASDAQ:GILD)

Consensus ROE: 31%

Number of Hedge Fund Investors in Q2 2024: 62

Gilead Sciences, Inc. (NASDAQ:GILD) is a sizeable drug company. It sells a variety of drugs such as those for AIDS, hepatitis, high blood pressure, and fungal infections. Gilead Sciences, Inc. (NASDAQ:GILD)’s sizeable financial resources, as evidenced by a cash pile of $3.7 billion have also allowed it to become one of the leading players in the high growth global market for HIV. The firm’s Biktarvy HIV treatment generated $3.2 billion in Q2 sales for an 8% growth. This enabled it to make a sizeable contribution to Gilead Sciences, Inc. (NASDAQ:GILD)’s HIV portfolio which generated $4.75 billion in sales during the quarter. Along with Descovy, another HIV drug that generated $485 million in revenue, Biktarvy accounted for 53.6% of Gilead Sciences, Inc. (NASDAQ:GILD)’s $6.9 billion revenue in Q2. The firm is also developing treatments for HIV, cholangitis, lung cancer, and gastrointestinal cancer called lenacapavir, seladelpar, trodelvy, domvanalimab, respectively. Their performance in trials, along with loss or gain of HIV market share are key drives of Gilead Sciences, Inc. (NASDAQ:GILD)’s hypothesis.

Parnassus Investments mentioned Gilead Sciences, Inc. (NASDAQ:GILD) in its Q1 2024 investor letter. Here is what the fund said:

“Gilead Sciences, a global biopharmaceutical company, saw its shares decline as a cancer drug failed to expand into additional lung indications, denting investor faith in the company’s oncology franchise. We maintain confidence in Gilead’s core HIV franchise and ability to expand into cancer treatment portfolios.”